Literature DB >> 31957551

Multivariable non-invasive association of isocitrate dehydrogenase mutational status in World Health Organization grade II and III gliomas with advanced magnetic resonance imaging T2 mapping techniques.

Maike Kern1,2, Timo A Auer2, Uli Fehrenbach2, Yasemin Tanyildizi3, Thomas Picht4, Martin Misch4, Edzard Wiener1.   

Abstract

AIM: To investigate multivariable analyses for noninvasive association of the isocitrate dehydrogenase (IDH) mutational status in grade II and III gliomas including evaluation of T2 mapping-sequences.
METHODS: Magnetic resonance imaging (MRI) examinations with histopathologically proven World Health Organization grade II and III gliomas were retrospectively enrolled. Multivariate receiver operating characteristics (ROC) analyses to associate IDH mutational status were performed containing quantitative T2 mapping analyses and qualitative characteristics (sex, age, localization, heterogeneity, oedema, necrosis and diameter). Relaxation times were calculated pixelwise by means of standardized ROI analyses. Interobserver variability also was tested.
RESULTS: Out of 32 patients (mean age: 50.7 years; range: 32-83), nine had grade II gliomas and 24 grade III, while 59.5% showed a positive IDH mutated state (IDHm) and 40.5% were wildtype (IDHw). Multivariable ROC analyses were calculated for relaxation time and range, localization and age with a cumulative 0.955 area under the curve (AUC) (p < 0.001), while central T2-relaxation time had by far the highest single variable sensitivity (AUC: 0.873; range: 0.762; age: 0.809; localization: 0.713). Age (cut off: 49 years; p = 0.031) and localization (p = 0.014) were the only qualitative parameters found to be significant as IDHw gliomas were older and IDHm gliomas were preferentially located fronto-temporal.
CONCLUSIONS: This is the first study evaluating quantitative T2 mapping sequences for association of the IDH mutational status in grade II and III gliomas demonstrating an association between relaxation time and mutational status. Analyses of T2 mapping relaxation times may even be suitable for predicting the correct IDH mutational state. Prognostic accuracy increases significantly in predicting the correct mutational state when combing T2 relaxation time characteristics and the qualitative MRI features age and localization.

Entities:  

Keywords:  Glioma; IDH1/2-state (isocitrate-dehydrogenase); MRI (magnetic resonance imaging); Multiparametric imaging; T2 mapping

Mesh:

Substances:

Year:  2020        PMID: 31957551      PMCID: PMC7140300          DOI: 10.1177/1971400919890099

Source DB:  PubMed          Journal:  Neuroradiol J        ISSN: 1971-4009


  33 in total

1.  Treatment outcomes and prognostic factors in patients with supratentorial low-grade gliomas.

Authors:  S-A Yeh; J-T Ho; C-C Lui; Y-J Huang; C-Y Hsiung; E-Y Huang
Journal:  Br J Radiol       Date:  2005-03       Impact factor: 3.039

2.  Advanced MR imaging techniques in the evaluation of nonenhancing gliomas: perfusion-weighted imaging compared with proton magnetic resonance spectroscopy and tumor grade.

Authors:  Neslin Sahin; Elias R Melhem; Sumei Wang; Jaroslaw Krejza; Harish Poptani; Sanjeev Chawla; Gaurav Verma
Journal:  Neuroradiol J       Date:  2013-11-07

3.  Proton MR spectroscopy of cerebral gliomas at 3 T: spatial heterogeneity, and tumour grade and extent.

Authors:  Alfonso Di Costanzo; Tommaso Scarabino; Francesca Trojsi; Teresa Popolizio; Domenico Catapano; Giuseppe M Giannatempo; Simona Bonavita; Maurizio Portaluri; Michela Tosetti; Vincenzo A d'Angelo; Ugo Salvolini; Gioacchino Tedeschi
Journal:  Eur Radiol       Date:  2008-04-04       Impact factor: 5.315

4.  Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel-based radiographic study of 146 low-grade gliomas.

Authors:  Y Wang; T Zhang; S Li; X Fan; J Ma; L Wang; T Jiang
Journal:  Eur J Neurol       Date:  2014-10-16       Impact factor: 6.089

5.  The role of diffusion-weighted imaging in patients with brain tumors.

Authors:  K Kono; Y Inoue; K Nakayama; M Shakudo; M Morino; K Ohata; K Wakasa; R Yamada
Journal:  AJNR Am J Neuroradiol       Date:  2001 Jun-Jul       Impact factor: 3.825

6.  Mesoscopic imaging of glioblastomas: Are diffusion, perfusion and spectroscopic measures influenced by the radiogenetic phenotype?

Authors:  Theo Demerath; Carl Philipp Simon-Gabriel; Elias Kellner; Ralf Schwarzwald; Thomas Lange; Dieter Henrik Heiland; Peter Reinacher; Ori Staszewski; Hansjörg Mast; Valerij G Kiselev; Karl Egger; Horst Urbach; Astrid Weyerbrock; Irina Mader
Journal:  Neuroradiol J       Date:  2016-11-19

Review 7.  Imaging Correlates of Adult Glioma Genotypes.

Authors:  Marion Smits; Martin J van den Bent
Journal:  Radiology       Date:  2017-08       Impact factor: 11.105

8.  Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in IDH-Mutant Lower Grade Gliomas.

Authors:  P P Batchala; T J E Muttikkal; J H Donahue; J T Patrie; D Schiff; C E Fadul; E K Mrachek; M-B Lopes; R Jain; S H Patel
Journal:  AJNR Am J Neuroradiol       Date:  2019-01-31       Impact factor: 3.825

9.  Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1/2 gene mutation using histogram analysis of diffusion-weighted imaging and dynamic-susceptibility contrast perfusion imaging.

Authors:  Seunghyun Lee; Seung Hong Choi; Inseon Ryoo; Tae Jin Yoon; Tae Min Kim; Se-Hoon Lee; Chul-Kee Park; Ji-Hoon Kim; Chul-Ho Sohn; Sung-Hye Park; Il Han Kim
Journal:  J Neurooncol       Date:  2014-09-10       Impact factor: 4.506

Review 10.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

View more
  1 in total

1.  Do gliosarcomas have distinct imaging features on routine MRI?

Authors:  Christoph J Maurer; Irina Mader; Felix Joachimski; Ori Staszewski; Bruno Märkl; Horst Urbach; Roland Roelz
Journal:  Neuroradiol J       Date:  2021-04-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.